Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADVC001
- Development stage
- Phase 2
- Lead developer
- Advancell
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
ADVC001 is a novel alpha-emitting radiopharmaceutical designed to target prostate-specific membrane antigen (PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). The drug consists of a high-affinity peptide ligand that binds to PSMA receptors on prostate cancer cells and is radiolabeled with lead-212 (212Pb), an alpha particle–emitting radionuclide. Upon binding to the tumor cell, 212Pb decays and emits alpha particles that induce double-stranded DNA breaks within a very short range, leading to highly localized cytotoxicity and minimizing damage to surrounding healthy tissue. The relatively short half-life of 212Pb (~10.6 hours) allows for potent therapeutic effects while reducing prolonged radiation exposure. ADVC001 is being developed by AdvanCell and is currently in Phase 1/2 clinical trials for mCRPC[1][2][3][5][7].
- Other names
- [212Pb]Pb-ADVC001Pb-212-ADVC001Pb212-ADVC001Pb 212-ADVC001
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on ADVC001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADVC001.